All participants exceeded twofold increase in spike-specific IgG, with geometric mean fold risk of 19.5 on day 57<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Oct. 17, 2023 (HealthDay News) — Two doses of a novel intranasal live-attenuated COVID-19 vaccine, CoviLiv, induce poly-antigenic immune response, according to a study presented at the annual meeting of the Infectious Diseases Society of America (IDWeek), held from Oct. 11 to 15 in Boston.<\/p>\n
Johanna Kaufmann, Ph.D., from Codagenix in Cambridge, Massachusetts, and colleagues characterized humoral immune responses in sera from six participants (at days 1, 29, and 57) with a spike-specific immunoglobulin G (IgG) enzyme-linked immunosorbent assay and microneutralization (MNT) and pseudovirus neutralization (PVN) assays. In peripheral blood mononuclear cells, T-cell functionality was analyzed.<\/p>\n
The researchers found that all participants exceeded a twofold increase in spike-specific IgG with a geometric mean fold rise of 19.5 on day 57 after two doses of CoviLiv. At this time point, neutralizing antibodies were induced 2.6- and 4.9-fold using MNT and PVN, respectively. On day 36 after vaccination, the interferon-\u00ce\u00b3 response by ELISpot after restimulation with the SNMO peptide pool increased 4.5- and 2.5-fold in the two- and one-dose cohorts, respectively. After placebo vaccination or in any group after restimulation with spike-only peptides, there was no increase seen in interferon-\u00ce\u00b3 response. Significant regimen-dependent SNMO-specific increases in interferon-\u00ce\u00b3, interleukin-2, and tumor necrosis factor-\u00ce\u00b1 response was confirmed by intracellular cytokine staining, especially in the CD4+ T-cell subset, including induction of polyfunctional CD4+ T cells.<\/p>\n
“The study findings provide a glimpse into what could be the next generation of COVID-19 vaccines that provide differentiated protection to more people,” Kaufmann said in a statement. “Vaccine administration by nose and easier storage can increase access to vaccinations for underserved areas across the world.”<\/strong><\/p>\n Codagenix engineered the CoviLiv vaccine.<\/p>\n Press Release<\/a><\/p>\n